Long-Term Evaluation of Oral KT-621 for Adults With Asthma Previously Treated in a KT-621 Study

What this Trial Is About

This research evaluates the long-term safety, tolerability, and effectiveness of KT-621 in adults with asthma who completed an earlier KT-621 asthma study. The study focuses on understanding how KT-621 behaves in the body over time and its potential to manage asthma symptoms. It is an open-label Phase 2b extension study designed for participants previously treated with KT-621. Participants will continue to receive oral KT-621 throughout the study. The treatment is administered as in the previous parent study, with no placebo group involved. This long-term extension aims to monitor how the drug performs over an extended period after initial treatment. During the study, participants will be monitored for side effects and changes in asthma control using questionnaires and lung function tests such as pre- and post-bronchodilator FEV1 measurements. Blood samples will be collected to measure KT-621 levels. Participants will also complete electronic diaries and attend scheduled visits for evaluations. The study duration extends up to 52 weeks with safety and efficacy assessments conducted throughout.

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study